J&J Wins Reversal of $482 Million Patent Verdict Over Stents
This article is for subscribers only.
Johnson & Johnson, the world’s largest seller of health-care products, didn’t infringe a doctor’s patent on heart devices, a U.S. appeals court ruled today in throwing out a $482 million jury verdict the man won.
The trial court erred in its interpretation of the patent owned by Bruce Saffran and, under the correct definition of key terms, J&J’s Cordis unit wasn’t using his invention, the U.S. Court of Appeals for the Federal Circuit in Washington said today in an opinion posted on its website.